Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, Abhyankar A, Toubiana J, Itan Y, Audry M, Nitschke P, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med. 2011;208(8):1635–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van de Veerdonk FL, Plantinga TS, Hoischen A, Smeekens SP, Joosten LA, Gilissen C, Arts P, Rosentul DC, Carmichael AJ, Smits-van der Graaf CA, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med. 2011;365(1):54–61.

Article  PubMed  Google Scholar 

Asano T, Utsumi T, Kagawa R, Karakawa S, Okada S. Inborn errors of immunity with loss-and gain-of-function germline mutations in STAT1.Clin Exp Immunol. 2022;212(2):96–106.

Depner M, Fuchs S, Raabe J, Frede N, Glocker C, Doffinger R, Gkrania-Klotsas E, Kumararatne D, Atkinson TP, Schroeder HW Jr, et al. The extended clinical phenotype of 26 patients with chronic mucocutaneous candidiasis due to gain-of-function mutations in STAT1. J Clin Immunol. 2016;36(1):73–84.

Article  CAS  PubMed  Google Scholar 

Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave Becerra JC, Ouachée-Chardin M, Fouyssac F, Girisha KM, Etzioni A, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016;127(25):3154–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mizoguchi Y, Tsumura M, Okada S, Hirata O, Minegishi S, Imai K, Hyakuna N, Muramatsu H, Kojima S, Ozaki Y, et al. Simple diagnosis of STAT1 gain-of-function alleles in patients with chronic mucocutaneous candidiasis. J Leukoc Biol. 2014;95(4):667–76.

Article  PubMed  PubMed Central  Google Scholar 

Bloomfield M, Kanderová V, Paračková Z, Vrabcová P, Svatoň M, Froňková E, Fejtková M, Zachová R, Rataj M, Zentsová I, et al. Utility of Ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-function mutation. J Clin Immunol. 2018;38(5):589–601.

Article  CAS  PubMed  Google Scholar 

Baris S, Alroqi F, Kiykim A, Karakoc-Aydiner E, Ogulur I, Ozen A, Charbonnier LM, Bakır M, Boztug K, Chatila TA, et al. Severe early-onset combined immunodeficiency due to heterozygous gain-of-function mutations in STAT1. J Clin Immunol. 2016;36(7):641–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kataoka S, Muramatsu H, Okuno Y, Hayashi Y, Mizoguchi Y, Tsumura M, Okada S, Kobayashi M, Sano C, Sato H, et al. Extrapulmonary tuberculosis mimicking Mendelian susceptibility to mycobacterial disease in a patient with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol. 2016;137(2):619-622.e611.

Article  CAS  PubMed  Google Scholar 

Giardino G, Somma D, Cirillo E, Ruggiero G, Terrazzano G, Rubino V, Ursini MV, Vairo D, Badolato R, Carsetti R, et al. Novel STAT1 gain-of-function mutation and suppurative infections. Pediatr Allergy Immunol. 2016;27(2):220–3.

Article  PubMed  Google Scholar 

Tabellini G, Vairo D, Scomodon O, Tamassia N, Ferraro RM, Patrizi O, Gasperini S, Soresina A, Giardino G, Pignata C, et al. Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol. 2017;140(2):553-564.e554.

Article  CAS  PubMed  Google Scholar 

Vargas-Hernández A, Mace EM, Zimmerman O, Zerbe CS, Freeman AF, Rosenzweig S, Leiding JW, Torgerson T, Altman MC, Schussler E, et al. Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol. 2018;141(6):2142-2155.e2145.

Article  PubMed  Google Scholar 

Soltész B, Tóth B, Shabashova N, Bondarenko A, Okada S, Cypowyj S, Abhyankar A, Csorba G, Taskó S, Sarkadi AK, et al. New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe. J Med Genet. 2013;50(9):567–78.

Article  PubMed  Google Scholar 

Pedraza-Sánchez S, Lezana-Fernández JL, Gonzalez Y, Martínez-Robles L, Ventura-Ayala ML, Sadowinski-Pine S, Nava-Frías M, Moreno-Espinosa S, Casanova JL, Puel A, et al. Disseminated tuberculosis and chronic mucocutaneous candidiasis in a patient with a gain-of-function mutation in signal transduction and activator of transcription 1. Front Immunol. 2017;8: 1651.

Article  PubMed  PubMed Central  Google Scholar 

Hartono SP, Vargas-Hernández A, Ponsford MJ, Chinn IK, Jolles S, Wilson K, Forbes LR. Novel STAT1 gain-of-function mutation presenting as combined immunodeficiency. J Clin Immunol. 2018;38(7):753–6.

Article  CAS  PubMed  Google Scholar 

Zimmerman O, Olbrich P, Freeman AF, Rosen LB, Uzel G, Zerbe CS, Rosenzweig SD, Kuehn HS, Holmes KL, Stephany D, et al. STAT1 gain-of-function mutations cause high total STAT1 levels with normal dephosphorylation. Front Immunol. 2019;10: 1433.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bernasconi AR, Yancoski J, Villa M, Oleastro MM, Galicchio M, Rossi JG. Increased STAT1 amounts correlate with the phospho-STAT1 Level in STAT1 gain-of-function defects. J Clin Immunol. 2018;38(7):745–7.

Article  PubMed  Google Scholar 

Zheng J, van de Veerdonk FL, Crossland KL, Smeekens SP, Chan CM, Al Shehri T, Abinun M, Gennery AR, Mann J, Lendrem DW, et al. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC). Eur J Immunol. 2015;45(10):2834–46.

Article  CAS  PubMed  Google Scholar 

Hiller J, Hagl B, Effner R, Puel A, Schaller M, Mascher B, Eyerich S, Eyerich K, Jansson AF, Ring J, et al. STAT1 gain-of-function and dominant negative STAT3 Mutations Impair IL-17 and IL-22 Immunity Associated with CMC. J Invest Dermatol. 2018;138(3):711–4.

Article  CAS  PubMed  Google Scholar 

McGonagle D, Ramanan AV, Bridgewood C. Immune cartography of macrophage activation syndrome in the COVID-19 era. Nat Rev Rheumatol. 2021;17(3):145–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Crow YJ, Stetson DB. The type I interferonopathies: 10 years on. Nat Rev Immunol. 2022;22(8):471–83.

Article  CAS  PubMed  Google Scholar 

Liu M, Liang S, Zhang C. NK Cells in autoimmune diseases: protective or pathogenic? Front Immunol. 2021;12: 624687.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kapellos TS, Bonaguro L, Gemünd I, Reusch N, Saglam A, Hinkley ER, Schultze JL. Human monocyte subsets and phenotypes in major chronic inflammatory diseases. Front Immunol. 2019;10: 2035.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ganguly D, Haak S, Sisirak V, Reizis B. The role of dendritic cells in autoimmunity. Nat Rev Immunol. 2013;13(8):566–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bloomfield M, Zentsova I, Milota T, Sediva A, Parackova Z. Immunoprofiling of monocytes in STAT1 gain-of-function chronic mucocutaneous candidiasis. Front Immunol. 2022;13: 983977.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parackova Z, Zentsova I, Vrabcova P, Sediva A, Bloomfield M. Aberrant tolerogenic functions and proinflammatory skew of dendritic cells in STAT1 gain-of-function patients may contribute to autoimmunity and fungal susceptibility. Clin Immunol. 2023;246: 109174.

Article  CAS  PubMed  Google Scholar 

Weinacht KG, Charbonnier LM, Alroqi F, Plant A, Qiao Q, Wu H, Ma C, Torgerson TR, Rosenzweig SD, Fleisher TA, et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol. 2017;139(5):1629-1640.e1622.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mössner R, Diering N, Bader O, Forkel S, Overbeck T, Gross U, Grimbacher B, Schön MP, Buhl T. Ruxolitinib Induces Interleukin 17 and ameliorates chronic mucocutaneous candidiasis caused by STAT1 gain-of-function mutation. Clin Infect Dis. 2016;62(7):951–3.

Article  PubMed  Google Scholar 

Meesilpavikkai K, Dik WA, Schrijver B, Nagtzaam NMA, Posthumus-van